Biodesix | GenomeWeb

Biodesix

Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.

The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.

Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.

Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.

BlueCross BlueShield of Florida began covering the test on March 15, and Health Care Services Corporation will begin coverage in June.

Norgen Biotek's sample prep  products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.

The company said it will use the funds to continue developing new companion diagnostics and expand commercialization of its VeriStrat and GeneStrat products

The company last year launched a PCR-based assay for identifying mutations in lung cancer patients and plans to release an NGS-based test later this year.

In a study looking at a total of 149 subjects with advanced unresectable melanoma, the test proved useful for distinguishing between good and poor responders.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.